BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Tuesday, April 23, 2024
See today's BioWorld Asia
Home
» Lee's inks alliance with Shenogen to develop checkpoint, TCM combo
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Lee's inks alliance with Shenogen to develop checkpoint, TCM combo
Nov. 29, 2017
By
Pearl Liu
No Comments
HONG KONG – Hong Kong-based has signed a co-development deal with Beijing Shenogen Pharma Group Ltd. to combine Lee's PD-L1 antibody with Shenogen's lead traditional Chinese medicine-derived small-molecule drug.
BioWorld Asia